WEBULL
WebtradeDownload

Ionis Pharmaceuticals (IONS) Shares Dropped, So What Is Behind The Latest Attention?

Simply Wall St · 3d ago

Ionis Pharmaceuticals (IONS) just picked up a key regulatory boost in Europe, with the EMA’s CHMP issuing a positive opinion to extend TRYNGOLZA’s indication for severe hypertriglyceridemia ahead of schedule.

The regulatory step comes against a tough trading backdrop for Ionis Pharmaceuticals, with the share price at US$42.94 after falling 18.9% over the past 90 days and 46.1% year to date. Even though the 5 year total shareholder return is still positive at 41.06%, this kind of early EMA progress may be read as investors reassessing both growth potential and risk around its RNA medicine pipeline.

Scan beyond Ionis Pharmaceuticals and this EMA milestone by reviewing hand-picked RNA and biotech peers with resilient balance sheets and cash flows in our list of solid balance sheet and fundamentals (25 results).

Ionis Pharmaceuticals now has a fresh EMA catalyst sitting beside a sharply lower share price. Does that mix argue for stepping in today, or for keeping cash back for a potentially cheaper entry later as valuation comes under the microscope next?

Most Popular Narrative: 49% Undervalued

Ionis Pharmaceuticals is framed by the most followed narrative as worth $83.64 per share, almost double the last close at $42.94. This puts the latest EMA progress and share price slide into a much sharper context for anyone weighing risk against potential upside.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage. Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

See why 19 investors see Ionis Pharmaceuticals as 49% undervalued.

Result: Fair Value of $83.64 (UNDERVALUED)

Still, the story can change quickly if key late stage approvals slip, or if pricing and reimbursement for broader severe hypertriglyceridemia use of Tryngolza prove tougher than analysts expect.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Next Steps

Strong opinions are forming around Ionis Pharmaceuticals, but you do not need to adopt anyone else's view. Move quickly, stress test the assumptions that matter most, then pressure check the upside by reviewing the 2 key rewards.

Looking for more investment ideas beyond Ionis Pharmaceuticals?

Do not stop your research with Ionis Pharmaceuticals. Broaden your watchlist with fresh ideas that line up with the kind of risk and reward you actually want.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.